Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism

Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 1168-1178

  Li, Ling ^a   Miao, Zongyu ^a   Liu, Rui ^a   Yang, Mengliu ^a   Liu, Hua ^b   Yang, Gangyi ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; CHOLESTEROL; FATTY ACID; INSULIN; LIRAGLUTIDE; MESSENGER RNA; TRIACYLGLYCEROL;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISORDERS OF HORMONE METABOLISM; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; GENE EXPRESSION PROFILING; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HYPERINSULINEMIA; HYPOADIPONECTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

3T3-L1 CELLS; ADIPONECTIN; ANIMALS; BLOTTING, WESTERN; CHOLESTEROL; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HYPERINSULINISM; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MICE; REAL-TIME POLYMERASE CHAIN REACTION; TRIGLYCERIDES;

EID: 82855168157     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00051     Document Type: Article

References (34)

1. Kieffer TJ, Habener JF. (1999) The glucagon-like peptides. Endocr. Rev. 20:876-913.
2. Agerso H, Vicini P. (2003) Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur. J. Pharm. Sci. 19:141-50.
3. Holst JJ, Orskov C, Nielsen OV, Schwartz TW. (1987) Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211:169-74.
4. Kreymann B, Williams G, Ghatei MA, Bloom SR. (1987) Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet. 2:1300-4.
5. Wettergren A, et al. (1993) Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38:665-73.
6. Naslund E, et al. (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord. 23:304-11.
7. Naslund E, et al. (1999) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 277:R910-16.
8. Edvell A, Lindstrom P. (1999) Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/-). Endocrinology. 140:778-83.
9. Willms B, et al. (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide- 1 (GLP-1)-(7-36) amide in type 2 (noninsulindependent) diabetic patients. J. Clin. Endocrinol. Metab. 81:327-32.
10. Rachman J, Barrow BA, Levy JC, Turner RC. (1997) Nearnormalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 40:205-11.
11. Meier JJ, et al. (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 53:654-62.
12. Knudsen LB, et al. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43:1664-9.
13. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. (1998) Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am. J. Clin. Nutr. 68:525-30.
14. Bregenholt S, et al. (2005) The long-acting glucagonlike peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330:577-84.
15. Mari A, et al. (2007) Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 30:2032-3.
16. Bregenholt S, et al. (2005) The long-acting glucagonlike peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330:577-84.
17. Li L, et al. (2008) Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes. Metab. 10:921-30.
18. Li K, et al. (2010) Effect of short hairpin RNAmediated adiponectin/Acrp30 down-regulation on insulin signaling and glucose uptake in the 3T3-L1 adipocytes. J. Endocrinol. Invest. 33:96-102.
19. Ling L, et al. (2009) The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-α (TNF-α) in vivo. Cytokine. 45:12-9.
20. Steele R, Wall JS, DeBodo RC. (1956) Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am. J. Physiol. 187:15-24.
21. Yu C, Gangyi Y, Ling L, Ling K, Wenwen C. (2009) The changes of glucose-lipid metabolism in ApoE-/- mice with high-fat induced insulin resistance. Chinese J. Diabetes. 17:590-603.
22. Marshall BA, Hansen PA, Ensor NJ, Ogden MA, Mueckler M. (1999) GLUT-1 or GLUT-4 transgenes in obese mice improve glucose tolerance but do not prevent insulin resistance. Am. J. Physiol. Endocrinol. Metab. 276:390-400.
23. Rothman DL, et al. (1995) Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 92:983-7.
24. Postic C, Dentin R, Girard J. (2004) Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab. 30:398-408.
25. Kraemer FB, Shen WJ. (2002) Hormone-sensitive lipase: control of intracellular tri-(di-) acylglycerol and cholesteryl ester hydrolysis. J. Lipid Res. 43:1585-94.
26. Zimmermann R, et al. (2003) Decreased fatty acid esterification compensates for the reduced lipolytic activity in hormone- sensitive lipase-deficient white adipose tissue. J. Lipid Res. 44:2089-99.
27. Laplante M, et al. (2003) PPAR-γ activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity. Diabetes. 52:291-9.
28. Mandard S, Muller M, Kersten S. (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell. Mol. Life Sci. 61:393-416.
29. Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J. (2004) The peroxisome proliferatoractivated receptor α (PPARα) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice. J. Biol. Chem. 279:28662-9.
30. Krapivner S, et al. (2008) Insulin-induced gene 2 involvement in human adipocyte metabolism and body weight regulation. J. Clin. Endocrinol. Metab. 93:1995-2001.
31. Horton JD, Goldstein JL, Brown MS. (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109:1125-31.
32. Yang T, et al. (2002) Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell. 110:489-500.
33. Yabe D, Brown MS, Goldstein JL. (2002) Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 99:12753-8.
34. Smith S, Witkowski A, Joshi AK. (2003) Structural and functional organization of the animal fatty acid synthase. Prog. Lipid Res. 42:289-317.